Last Updated on May 13, 2022 by GlobeNewsWire
Geneva, Switzerland, May 13, 2022 – Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, and Dr. Robert Lütjens, Head of Discovery – Biology, will be attending 22nd Bio€quity Europe Conference taking place May 16 – 18, 2022, in Milan, Italy.
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Japanese
Portuguese
Russian
Spanish